Advertisement

Current Urology Reports

, Volume 4, Issue 6, pp 466–471 | Cite as

Erectile dysfunction in the cardiac patient

  • Robert A. Kloner
Article

Abstract

Erectile dysfunction (ED) often is caused by endothelial dysfunction and may be a sign that a patient has vascular disease elsewhere in the body. Risk factors for coronary artery disease such as lipid abnormalities, smoking, diabetes, and hypertension also are risk factors for ED. Oral therapy for ED, such as sildenafil, inhibits phosphodiesterase-5 (PDE-5) and the breakdown of cyclic guanosine monophosphate. PDE-5 inhibitors have been shown to be safe and effective for the therapy for ED, but remain contraindicated in patients receiving organic nitrates. These agents are mild vasodilators and are being investigated for their treatment potential for patients with pulmonary hypertension, heart failure, and endothelial dysfunction.

Keywords

Erectile Dysfunction Brachial Artery Tadalafil Iloprost Vardenafil 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Treasure CB, Klein JL, Weintraub WS, et al.: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995, 322:481–487.CrossRefGoogle Scholar
  2. 2.
    Creager MA, Cooke JP, Mendelsohn ME, et al.: Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990, 86:228–234.PubMedCrossRefGoogle Scholar
  3. 3.
    Meredith IT, Currie KE, Anderson TJ, et al.: Postischemic vasodilation in human forearm is dependent on endothelium — derived nitric oxide. Am J Physiol 1996, 270:H1435-H1440.PubMedGoogle Scholar
  4. 4.
    Panza JA, Quyyumi AA, Brush JE, Epstein SE: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990, 323:22–27.PubMedCrossRefGoogle Scholar
  5. 5.
    Weissberg PL, Rudd JH: Atherosclerosis Biology and Epidemiology of Disease in Textbook of Cardiovascular Medicine, edn 2. Edited by Topol EJ. Philadelphia: Lippincott Williams & Wilkins; 2002:3–14.Google Scholar
  6. 6.
    Mancini GB, Henry GC, Macaya C, et al.: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996, 94:258–265.PubMedGoogle Scholar
  7. 7.
    Kloner RA, Jarow JP: Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999, 83:576–582.PubMedCrossRefGoogle Scholar
  8. 8.
    Azadzoi KM, Siroky MB, Goldstein I: Study of etiologic relationship of arterial atherosclerosis to corporal veno-occlusive dysfunction in the rabbit. J Urol 1996, 155:1795–1800.PubMedCrossRefGoogle Scholar
  9. 9.
    Feldman HA, Goldstein I, Hatzichristou DG, et al.: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994, 151:54–61.PubMedGoogle Scholar
  10. 10.
    Virag R, Bouilly P, Frydman D: Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985, 322:181–184.CrossRefGoogle Scholar
  11. 11.
    Wei M, Macera CA, Davis DR, et al.: Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994, 140:930–937.PubMedGoogle Scholar
  12. 12.
    Klein R, Klein BE, Lee RE, et al.: Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care 1996, 19:135–141.PubMedCrossRefGoogle Scholar
  13. 13.
    Kloner RA, Speakman M: Erectile dysfunction and atherosclerosis. Curr Atheroscler Rep 2002, 4:397–401.PubMedGoogle Scholar
  14. 14.
    Feldman HA, Johannes CB, Derby CA, et al.: Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prevent Med 2000, 30:328–338. Prospective study confirming that risk factors for ED also are cardiovascular risk factors. This article also showed that passive smoke and cigar smoking are risk factors.CrossRefGoogle Scholar
  15. 15.
    Kloner RA, Mullin SH, Shook T, et al.: Erectile dysfunction in the cardiac patient: How common and should we treat? J Urol 2003, 170:S46-S50.PubMedCrossRefGoogle Scholar
  16. 16.
    Kim SW, Paick JS, Park DW, et al.: Potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction. Urology 2001, 58:441–445. Men who did not respond to pharmacologic erection test (10 _g prostaglandin E1) were more likely to have risk factors for cardiac disease and were more likely to have a positive exercise test (15.7%) than those who responded (0%).PubMedCrossRefGoogle Scholar
  17. 17.
    Pritzker MR: The penile stress test: a window to the hearts of man? Circulation 1999, 100:I-711.Google Scholar
  18. 18.
    Goldstein I, Lue TF, Padma-Nathan H, et al.: Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998, 338:1397–1404.PubMedCrossRefGoogle Scholar
  19. 19.
    Conti CR, Pepine CJ, Sweeney M: Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999, 83:29C-34C.PubMedCrossRefGoogle Scholar
  20. 20.
    Kloner RA, Brown M, Prisant LM, et al.: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 2001, 14:70–73. Side effects of sildenafil were not aggravated by antihypertensive medicines. Sildenafil was highly effective for ED in hypertensive men taking antihypertensive medication.PubMedCrossRefGoogle Scholar
  21. 21.
    Pickering TG, Mancia G, Glasser DB, et al.: Safety of Viagra (sildenafil citrate) in men with erectile dysfunction and arterial hypertension who are taking multiple antihypertensive treatments. Am J Hypertens 2002, 15(suppl 1):A55-A56.CrossRefGoogle Scholar
  22. 22.
    Zusman RM, Morales A, Glasser DB, Osterloh IH: Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999, 83:35C-44C.PubMedCrossRefGoogle Scholar
  23. 23.
    Fogari R, Zoppi A, Poletti L, et al.: Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001, 14:27–31. One of the first studies showing that an antihypertensive agent (in this case valsartan) actually could be beneficial to men with ED.PubMedCrossRefGoogle Scholar
  24. 24.
    Herrmann HC, Chang G, Klugherz BD, et al.: Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000, 342:1622–1626.PubMedCrossRefGoogle Scholar
  25. 25.
    Arruda-Olson AM, Mahoney DW, Nehra A, et al.: Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized, crossover trial. JAMA 2002, 287:719–725. An important study showing that, when levels of stress were achieved and were at least as great or greater than that associated with sexual activity, sildenafil had no adverse effects on exercise tolerance or the development of ischemic wall motion abnormalities by echocardiography.PubMedCrossRefGoogle Scholar
  26. 26.
    Fox KM, Thadani U, Ma PT, Nash SD: Time to onset of limiting angina during treadmill exercise in men with erectile dysfunction and stable chronic angina: effect of sildenafil citrate (Abstract). Circulation 2001, 107:II601.Google Scholar
  27. 27.
    Thadani U, Smith W, Nash S, et al.: The effect of vardenafil, a potent and highly selective phosphodiesterase -5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002, 40:2006–2012.PubMedCrossRefGoogle Scholar
  28. 28.
    Patterson D, MacDonald TM, Effron MB, et al.: Tadalafil does not affect time to ischemia during exercise stress testing in patients with coronary artery disease. Circulation 2002, 106(suppl 2):II-330.Google Scholar
  29. 29.
    Padma-Nathan H, Eardley I, Kloner RA, et al.: A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2002, 60(suppl 2B):67–90.PubMedCrossRefGoogle Scholar
  30. 30.
    Shakir SA, Wilton LV, Boshier A, et al.: Cardiovascular events in users of sildenafil: results from the first phase of prescription event monitoring in England. BMJ 2001, 322:651–652.PubMedCrossRefGoogle Scholar
  31. 31.
    Emmick JT, Stuewe SR, Mitchell M: Overview of the cardiovascular effects of tadalafil. Eur Heart J 2002, 24(suppl H):H32-H47.Google Scholar
  32. 32.
    Wysowski DK, Farinas E, Swartz L: Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 2002, 89:1331–1334. Report from the FDA showing no increase in reported versus expected deaths from the use of sildenafil.PubMedCrossRefGoogle Scholar
  33. 33.
    Muller JE, Mittleman MA, Maclure M, et al.: Triggering myocardial infarction by sexual activity. JAMA 1996, 275:1405–1409.PubMedCrossRefGoogle Scholar
  34. 34.
    Cheitlin MD, Hutter AM, Brindis RG, et al.: ACC/AHA Expert Consensus Document. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999, 33:273–282.PubMedCrossRefGoogle Scholar
  35. 35.
    DeBusk R, Drory Y, Goldstein I, et al.: Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 2000, 86:175–181. Provides a practical approach to the cardiac patient with sexual dysfunction. Describes an algorithm for dealing with patients at low, intermediate, and high cardiovascular risk.PubMedCrossRefGoogle Scholar
  36. 36.
    Zusman RM, Pisant LM, Brown JM: Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. J Hypertens 2000, 18:1865–1869.PubMedCrossRefGoogle Scholar
  37. 37.
    Kloner RA, Mohan P, Segerson T, et al.: Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: a post-hoc analysis of five placebo-controlled clinical trials. J Am Coll Cardiol 2003, 41(suppl A):276A-277A.CrossRefGoogle Scholar
  38. 38.
    Kloner RA, Mitchell M, Emmick JT: Cardiovascular effects of tadalafil in patients on commonly used classes of antihypertensive therapy. Am J Cardiol, In press, 2003.Google Scholar
  39. 39.
    Webb DJ, Freestone S, Allen MJ, Muirhead GJ: Sildenafil citrate and blood pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999, 83:21C-28C.PubMedCrossRefGoogle Scholar
  40. 40.
    Kloner RA, Emmick J, Bedding A, Humen D: Pharmacodynamic interactions between tadalafil and nitrates. J Am Coll Cardiol 2002, 39(suppl A):291A.CrossRefGoogle Scholar
  41. 41.
    Oliver JJ, Bell K, Leekie SM, Webb DJ: Interaction between glyceryl trinitrate and sildenafil citrate (Viagra) may last less than 4 hours. Int J Impot Res 2002, Supplement:S22.Google Scholar
  42. 42.
    DeSouza C, Parulkar A, Lumpkin D, et al.: Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002, 25:1136–1139.CrossRefGoogle Scholar
  43. 43.
    Katz SD, Balidemaj R, Homma S, et al.: Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000, 36:845–851.PubMedCrossRefGoogle Scholar
  44. 44.
    Wilkens H, Guth A, König J, et al.: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001, 104:1218–1222.PubMedGoogle Scholar
  45. 45.
    Ghofrani HA, Wiedemann R, Rose F, et al.: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002, 360:895–900.PubMedCrossRefGoogle Scholar
  46. 46.
    Lepore JJ, Maroo A, Pereira NL, et al.: Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002, 90:677–680.PubMedCrossRefGoogle Scholar
  47. 47.
    Michelakis E, Tymachak W, Lien D, et al.: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Circulation 2002, 105:2398–2403. Thirteen patients with pulmonary hypertension had hemodynamic measures with inhaled (iNO), sildenafil, or both. Sildenafil decreased pulmonary vascular resistance and there was an additive effect with iNO. Sildenafil improved cardiac index, but iNO alone did not.PubMedCrossRefGoogle Scholar
  48. 48.
    Bocchi EA, Guimarães G, Mocelin A, et al.: Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure. Circulation 2002, 106:1097–1103.PubMedCrossRefGoogle Scholar
  49. 49.
    Lachmann JS, Lewis GD, Systom DM, et al.: Sildenafil improves hemodynamic and exercise tolerance in advanced heart failure. Circulation 2002, 106(suppl 2):II-469.Google Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Robert A. Kloner
    • 1
  1. 1.Heart InstituteGood Samaritan HospitalLos AngelesUSA

Personalised recommendations